Ahn MJ - Search Results

1

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).

Ou SI, Nishio M, Ahn MJ, Mok T, Barlesi F, Zhou C, Felip E, de Marinis F, Kim SW, Pérol M, Liu G, Migliorino MR, Kim DW, Novello S, Bearz A, Garrido P, Mazieres J, Morabito A, Lin HM, Yang H, Niu H, Zhang P, Kim ES. Ou SI, et al. Among authors: ahn mj. J Thorac Oncol. 2022 Dec;17(12):1404-1414. doi: 10.1016/j.jtho.2022.08.018. Epub 2022 Sep 10. J Thorac Oncol. 2022. PMID: 36096442 Free article.

2

Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?

Ahn MJ, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Ki CS, Park CK, Holmes AJ, Jänne PA, Park K. Ahn MJ, et al. Among authors: ahn js. Clin Cancer Res. 2008 Jun 15;14(12):3860-6. doi: 10.1158/1078-0432.CCR-07-4608. Clin Cancer Res. 2008. PMID: 18559606 Clinical Trial.

3

Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.

Kim HS, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ. Kim HS, et al. Among authors: ahn js, ahn mj. Oncology. 2009;76(4):239-46. doi: 10.1159/000205386. Epub 2009 Feb 25. Oncology. 2009. PMID: 19246948

4

Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.

Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Jänne PA, Ahn MJ. Park S, et al. Among authors: ahn js, ahn mj. J Thorac Oncol. 2009 Jul;4(7):809-15. doi: 10.1097/JTO.0b013e3181a94af4. J Thorac Oncol. 2009. PMID: 19487967 Free article.

5

Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.

Uhm JE, Park BB, Ahn MJ, Lee J, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Park K. Uhm JE, et al. Among authors: ahn js, ahn mj. J Thorac Oncol. 2009 Sep;4(9):1136-43. doi: 10.1097/JTO.0b013e3181b270a7. J Thorac Oncol. 2009. PMID: 19687764 Free article. Clinical Trial.

6

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.

Lee DH, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Na II, Lee JC, Ryoo BY, Yang SH. Lee DH, et al. Among authors: ahn js, ahn mj. Cancer. 2010 Jan 1;116(1):132-6. doi: 10.1002/cncr.24719. Cancer. 2010. PMID: 19904804 Free article. Clinical Trial.

7

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.

Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW. Lee DH, et al. Among authors: ahn js, ahn mj. Clin Cancer Res. 2010 Feb 15;16(4):1307-14. doi: 10.1158/1078-0432.CCR-09-1903. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145166 Clinical Trial.

8

Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy.

Sun JM, Park JO, Won YW, Kim JH, Yun J, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Sun JM, et al. Among authors: ahn js, ahn mj. J Thorac Oncol. 2010 Apr;5(4):540-5. doi: 10.1097/JTO.0b013e3181d3504d. J Thorac Oncol. 2010. PMID: 20195170 Free article.

9

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.

Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ. Kim ST, et al. Among authors: ahn js, ahn mj. Cancer. 2010 Jun 15;116(12):3025-33. doi: 10.1002/cncr.25130. Cancer. 2010. PMID: 20564408 Free article.

10

Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era.

Ahn MJ, Lee J, Park YH, Ahn JS, Ziogas A, Zell JA, Park K, Ou SH. Ahn MJ, et al. Among authors: ahn js. J Thorac Oncol. 2010 Aug;5(8):1185-96. doi: 10.1097/JTO.0b013e3181e2f624. J Thorac Oncol. 2010. PMID: 20592628 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

758 results

Search Page